Background: The aim of this study was to investigate the effect of GnRH antagonists (GnRH-ant) on follicular fluid vascular endothelial growth factor (FF VEGF). Methods: Sixty women undergoing assisted reproduction were randomised (computer-generated randomisation list) and assigned to two different GnRH analogue regimens: GnRH agonist (GnRH-a) (Group A; n = 30) and GnRH-ant (Group B; n = 30). Results: Mean (S.D.) FF VEGF concentrations were 1598 612 pg/mL and 2906 1558 pg/mL for Groups A and B, respectively ( p < 0.001). In the women treated with GnRH-ant, we found a statistically significant reduction in serum LH levels (1.72 0.74 IU/L in Group A versus 0.93 0.43 IU/L in Group B, p < 0.001), in serum oestradiol (E2) levels (1562.1 410.7 pg/mL in Group A versus 1214.67 779.9 pg/mL in Group B, p < 0.05), in FF E2 levels (1146 593 ng/mL in Group A versus 621 435 ng/mL in Group B, p < 0.05), and in FF androstenedione levels (136 55 ng/mL in Group A versus 78 31 ng/mL in Group B, p < 0.001), as well as a reduction in the number of pregnancies, though not statistically significant (23.3% in Group A versus 16.6% in Group B). Conclusion: The increase in FF VEGF levels in women treated with GnRH-ant might be explained by a suppression of LH and E2 levels.
Follicular fluid vascular endothelial growth factor concentrations are increased during GnRH antagonist/FSH ovarian stimulation cycles / Ferrari, Bruno; Pezzuto, A; Barusi, L; Coppola, F.. - In: EUROPEAN JOURNAL OF OBSTETRICS, GYNECOLOGY, AND REPRODUCTIVE BIOLOGY. - ISSN 0301-2115. - 124 (1):(2006), pp. 70-76. [10.1016/j.ejogrb.2005.08.017]
Follicular fluid vascular endothelial growth factor concentrations are increased during GnRH antagonist/FSH ovarian stimulation cycles.
FERRARI, Bruno;
2006-01-01
Abstract
Background: The aim of this study was to investigate the effect of GnRH antagonists (GnRH-ant) on follicular fluid vascular endothelial growth factor (FF VEGF). Methods: Sixty women undergoing assisted reproduction were randomised (computer-generated randomisation list) and assigned to two different GnRH analogue regimens: GnRH agonist (GnRH-a) (Group A; n = 30) and GnRH-ant (Group B; n = 30). Results: Mean (S.D.) FF VEGF concentrations were 1598 612 pg/mL and 2906 1558 pg/mL for Groups A and B, respectively ( p < 0.001). In the women treated with GnRH-ant, we found a statistically significant reduction in serum LH levels (1.72 0.74 IU/L in Group A versus 0.93 0.43 IU/L in Group B, p < 0.001), in serum oestradiol (E2) levels (1562.1 410.7 pg/mL in Group A versus 1214.67 779.9 pg/mL in Group B, p < 0.05), in FF E2 levels (1146 593 ng/mL in Group A versus 621 435 ng/mL in Group B, p < 0.05), and in FF androstenedione levels (136 55 ng/mL in Group A versus 78 31 ng/mL in Group B, p < 0.001), as well as a reduction in the number of pregnancies, though not statistically significant (23.3% in Group A versus 16.6% in Group B). Conclusion: The increase in FF VEGF levels in women treated with GnRH-ant might be explained by a suppression of LH and E2 levels.File | Dimensione | Formato | |
---|---|---|---|
Ferrari Follicular fluid.pdf
non disponibili
Tipologia:
Documento in Post-print
Licenza:
Creative commons
Dimensione
173.81 kB
Formato
Adobe PDF
|
173.81 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.